Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check26 days agoChange Detected- Removal of a general government funding status notice from the page; the study details, eligibility criteria, locations, and contacts remain unchanged.SummaryDifference0.1%

- Check33 days agoChange DetectedLocation list updated from 'Tainan City, Taiwan, 704' to 'Tainan, Taiwan, 704' in the Locations section. The site ID remains the same.SummaryDifference0.0%

- Check40 days agoChange DetectedResults for NCT03740165 have been posted, including primary and secondary outcomes, along with updated results posting dates on the study page.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded Cali, Valle del Cauca Department, Colombia, 760042 as a study location and removed Santiago de Cali, Valle del Cauca Department, Colombia, 760042. Also updated the page to display 'Last Update Posted (Estimated)'.SummaryDifference0.0%

- Check69 days agoChange DetectedMajor change: updated operating status notice and version to v3.2.0, replacing v3.1.0; outlines funding lapse effects and where to check details.SummaryDifference1.0%

Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.